Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | active not recruiting | Phase 3 | 1,167 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07145333 | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms(Drug-SNP) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY |
| 1 |
| Sep 8, 2025 |
| clinicaltrials |
| NCT05459844 | A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | active not recruiting | Phase 3 | 196 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | not yet recruiting | Phase 3 | 740 | Tempest TherapeuticsINDUSTRY | 0 | Sep 3, 2025 | clinicaltrials |
| NCT03340896 | Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT(SALTORL) | active not recruiting | Phase 3 | 256 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT06492460 | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 422 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | active not recruiting | Phase 2 / Phase 3 | 127 | ALX Oncology Inc.INDUSTRY | 12 | Aug 7, 2025 | clinicaltrials |
| NCT06095141 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6) | recruiting | Phase 2 / Phase 3 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06250972 | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer(PTCA199-11) | recruiting | Phase 3 | 210 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT06841172 | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC | recruiting | Phase 3 | 132 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT01952223 | A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse(PEACE2) | active not recruiting | Phase 3 | 761 | UNICANCEROTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03348150 | Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.(PERISCOPEII) | active not recruiting | Phase 3 | 102 | The Netherlands Cancer InstituteOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC(SHARP) | recruiting | Phase 3 | 340 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05224141 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | active not recruiting | Phase 3 | 460 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Jul 8, 2025 | clinicaltrials |
| NCT05943795 | A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma | active not recruiting | Phase 3 | 589 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06954246 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 450 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07021261 | Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | not yet recruiting | Phase 3 | 440 | Fudan UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07016737 | Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy(ESO-Nanjing12) | enrolling by invitation | Phase 3 | 79 | Ye jinjunOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05346224 | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | active not recruiting | Phase 3 | 900 | Shanghai Henlius BiotechINDUSTRY | 4 | Jun 10, 2025 | clinicaltrials |
| NCT07008716 | Omitting CTV for Primary Tumor in LS-SCLC | recruiting | Phase 3 | 852 | Sun Yat-sen UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05219318 | Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors(SPICI) | active not recruiting | Phase 3 | 22 | University Hospital, BordeauxOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04328948 | A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC(ARMADILLO) | recruiting | Phase 3 | 280 | National Cancer Center, JapanOTHER_GOV | 1 | May 22, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04521153 | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 / Phase 3 | 294 | Shanghai Zhongshan HospitalOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03562637 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | active not recruiting | Phase 3 | 575 | OBI Pharma, IncINDUSTRY | 13 | May 9, 2025 | clinicaltrials |
| NCT02998385 | Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)(SANTAL) | active not recruiting | Phase 3 | 342 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02999087 | Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)(REACH) | active not recruiting | Phase 3 | 707 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03576417 | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck(NIVOPOSTOP) | active not recruiting | Phase 3 | 680 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT04068103 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | active not recruiting | Phase 2 / Phase 3 | 635 | NRG OncologyOTHER | 3 | May 7, 2025 | clinicaltrials |
| NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | not yet recruiting | Phase 3 | 94 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT03592472 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | recruiting | Phase 3 | 413 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 6 | Apr 13, 2025 | clinicaltrials |
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | recruiting | Phase 3 | 1,100 | Dr Rajendra A. BadweOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03168880 | A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer(TNBC) | active not recruiting | Phase 3 | 720 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | not yet recruiting | Phase 2 / Phase 3 | 100 | Zhejiang Cancer HospitalOTHER | 0 | Apr 4, 2025 | clinicaltrials |
| NCT06907602 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma(ONTRESCC) | recruiting | Phase 2 / Phase 3 | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04296175 | Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)(CITRINE) | active not recruiting | Phase 3 | 808 | Fudan UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT05489289 | A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | recruiting | Phase 3 | 570 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03895359 | Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma(TACE) | recruiting | Phase 3 | 128 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06861777 | Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 / Phase 3 | 474 | YIN LIOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer(NEEDS) | recruiting | Phase 3 | 1,020 | Karolinska University HospitalOTHER | 5 | Mar 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 8, 2025source: clinicaltrials